New molecular mechanisms of action of camptothecin-type drugs

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3301-3305

  Legarza, Kathleen ^a   Yang, Li Xi ^a,b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ST MARY S MEDICAL CENTER   (United States)

Author keywords

Camptothecin; Molecular mechanisms of action and gene expression; Review; Topoisomerase I inhibitor

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; FLUOROURACIL; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; COLORECTAL CANCER; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33750737700     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail HT and Sim GA: The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 88: 3888-3890, 1966.
2. Legarza K and Yang L-X: Novel camptothecin derivatives. In Vivo 19: 283-292, 2005.
3. Tse YC, Kirkegaard K and Wang JC: Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem 255: 5560-5565, 1980.
4. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
5. Stewert L, Redinbo MR, Xiayang Q, Hol WGJ and Cahmpoux JJ: A model for the mechanism of human topoisomerase I. Science 279: 1534-1541, 1998.
6. Redinbo MR, Stewart L, Kuhn P, Champoux J and Hol WGJ: Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513, 1998.
7. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB and Stewert L: The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Aca Sci 99: 15387-15392, 2002.
8. Antony S, Theruvathu JA, Brooks PJ, Lesher D-T, Redindo M and Pommier Y: Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2′-deoxyguanosine. Nucleic Acids Res 32: 5685-5692, 2004.
9. Pourquier P, Loktionova NA, Pegg AE and Pommier Y: Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61: 53-58, 2001.
10. Jaxel C, Capranico G, Kerrigan D, Kohn KW and Pommier Y: Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266: 20418-20423, 1991.
11. Kang MR, Muller MT and Chung IK: Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin. J Biol Chem 279: 12535-12541, 2004.
12. Hsiang Y-H, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
13. Tsao YP, Russo A, Nyamuswa, Silber R and Liu LF: Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53: 5908-5914, 1993.
14. Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121, 1995.
15. Wu J, Yin M-B, Hapke G, Toth K and Rustum YM: Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmocol 61: 742-748, 2002.
16. Bendixen C, Thomsen B, Alsner J and Westergaard O: Camptothecin- stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 29: 5613-5619, 1990
17. Collins I, Weber A and Levens D: Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 21: 8437-8451, 2001.
18. Wu J and Liu LF: Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res 25: 4181-4186, 1997.
19. Mosesso P, Pichierri P, Franchiitto A and Paitti F: Evidence that camptothecin-induced aberrations in the G(2) phase of cell cycle of Chinese hamster ovary (CHO) cell lines is associated with transcription. Mutat Res 452: 189-195, 2000.
20. Morris EJ and Geller H: Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol 134: 757-770, 1996.
21. McCrudden KW, Yokoi A, Thosani A, Soffer SZ, Kim ES, Huang J, Manley C, O'toole K, Yamashiro DJ, Kandel JJ and Middlesworth W: Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37: 857-861, 2002.
22. Kamiyama H, Takano S, Tsuboi K and Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/ vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131: 205-213, 2005.
23. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF and Jodrell DI: Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 9: 2856-2865, 2003.
24. Ullmannova V and Haskovec C: Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2. Neoplasma 51: 175-180, 2004.
25. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA and Miyamoto S: NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 275: 9501-9509, 2000.
26. Carson JP, Zhang N, Frampton GM, Gerry NP, Lenburg ME and Christman MF: Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Res 64: 2096-2104, 2004.
27. Cliby WA, Lewis KA, Lilly KA, Lilly KK and Kaufmann SH: S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606, 2002.
28. Siu WY, Lau A, Arooz T, Chow JP, Ho HT and Poon RY: Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. Mol Cancer Ther 3: 621-632, 2004.
29. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM and Kaufmann SH: The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 280: 14349-14355, 2005.
30. Wang H, Wang X, Shou X-Y, Chen DJ, LI GC, Iliakis G and Wang Y: Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res 62: 2483-2487, 2002.
31. Deptala A, Li X, Bender E, Cheng W, Traganos F and Darzynkiewicz Z: Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin. Int J Oncol 15: 861-871, 1999.
32. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63: 8791-8812, 2003.
33. Desai SD, Liu LF, Vazguez-Abad D and D'Arpa P: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 272: 24159-24164, 1997.
34. Desai SD, Zhang H, Rodriguez-Bauman A, Yang J-M, Wu X, Gounder MK, Rubin EH and Liu LF: Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 23: 2341-2350, 2003.
35. Mao Y, Sun M, Desai SD and Liu LF: SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Nat Acad Sci 97: 4046-4051, 2000.
36. Zhang H-F, Tomida A, Koshimizu R, Ogiso Y, Lei S and Tsuruo: Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res 64: 1114-1121, 2004.
37. Furuta T, Takemura H, Liao Z-Y, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, Nussenzweig A, Aladjem MI, Bonner WM and Pommier Y: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303-20312, 2003.
38. Shao R-G, Cao C-X, Zhang H, Kohn KW, Wold MS and Pommier Y: Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. Eur Mol Biol Organ J 18: 1397-1406, 1999.
39. Adachi N, So S and Koyama H: Loss of nonhomologous end joining confers comptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J Biol Chem 279: 37343-37348, 2004.
40. Jacob S, Aguado M, Fallik D and Praz F: The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61: 6555-6562, 2001.
41. Jacob S, Miquel C, Sarasin A and Praz F: Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines. Nucleic Acid Res 33: 106-113, 2005.